News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Diabetes treatment more widely available


Diabetes treatment more widely available

Government drug funder PHARMAC is giving more people the chance to have the new generation diabetes treatment pioglitazone (Actos).

The new access criteria, which further reflect PHARMAC’s commitment to giving more New Zealanders access to subsidised medicines, take effect from 1 August 2005.

Pioglitazone (Actos) was first subsidised 1 September 2004 for people with Type 2 diabetes, both as a therapy on its own or for use in combination with drugs known as sulphonylureas (such as glibenclamide).

However, some clinicians have commented that more people could potentially benefit from pioglitazone than just those specified in the original listing criteria, says PHARMAC’s Chief Executive Wayne McNee.

“We’ve taken these comments on board and our response is to widen access to give more people the opportunity to have pioglitazone prescribed,” Wayne McNee says.

“Diabetes is a disease that is of growing concern with an increase in its prevalence as people’s lifestyles change. Many people with Type 2 diabetes can control their condition through changing their lifestyle or diet, however others need medicines such as pioglitazone which can help to control their blood glucose levels.”

Pioglitazone is a medicine that improves the body’s ability to use insulin, the hormone which reduces blood glucose levels. This leads to better control of blood sugar levels and helps avoid the many complications which diabetes can cause.

Under the changes, pioglitazone will also be subsidised for some people who use insulin, and for some people in combination with metformin.

PHARMAC is anticipating spending on pioglitazone will be in the region of $4 million per annum within three years.

[ends]


© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>


Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>

ALSO:

Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
K Emma Ng's Old Asian, New Asian

This book, written by a young second-generation Chinese New Zealander, gives many examples of the racism that Asian New Zealanders experience. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION